|
|
Post by jckrdu on Oct 30, 2014 18:25:23 GMT
Phase 2 heart attack trial just appeared on clinicaltrials.gov. Identifier is NCT02277613. First patient should be treated before the end of 2014, per the CEO at the Mesa conference. Phase 1 results (impressive IMO as they show efficacy) can be found on the company website. Should see a PR any day on the start of this trial, and the grant funding that's helping to support it. www.clinicaltrials.gov/ct2/results?term=NCT02277613&Search=Search |
|
|
|
Post by selluwud on Oct 31, 2014 15:05:19 GMT
Phase 2 heart attack trial just appeared on clinicaltrials.gov. Identifier is NCT02277613. First patient should be treated before the end of 2014, per the CEO at the Mesa conference. Phase 1 results (impressive IMO as they show efficacy) can be found on the company website. Should see a PR any day on the start of this trial, and the grant funding that's helping to support it. www.clinicaltrials.gov/ct2/results?term=NCT02277613&Search=Searchshould be soon, this stock has a little life in it today pps wise, but no volume. |
|
|
|
Post by jckrdu on Oct 31, 2014 15:22:56 GMT
Phase 2 heart attack trial just appeared on clinicaltrials.gov. Identifier is NCT02277613. First patient should be treated before the end of 2014, per the CEO at the Mesa conference. Phase 1 results (impressive IMO as they show efficacy) can be found on the company website. Should see a PR any day on the start of this trial, and the grant funding that's helping to support it. www.clinicaltrials.gov/ct2/results?term=NCT02277613&Search=Searchshould be soon, this stock has a little life in it today pps wise, but no volume. Next PR should get it back to the $1.50 to $1.75 range. It just sold-off over the summer when they announced the delay to completing stroke enrollment. Money is starting (slowly) to move back in. Lot of news coming in the last 8 weeks of the year. |
|
|
|
Post by jckrdu on Oct 31, 2014 17:07:54 GMT
Sell, RLC: Found some other interesting information... The UC trial has been updated (see clinicaltrials.gov link below) with new locations. The updates were made 2 days ago on 10/29. As you know, the UC trial was the one funded and run by Pfizer, and early this year they announced it did not meet the Phase 2 efficacy endpoints. That was the reason ATHX plummeted from the $4s to the low $1s. Well, these changes on clinicaltrials.gov include new sites and changes to the status of the trial from "closed" to "Active Not Recruiting". While I can't be sure, it appears that this trial is continuing on in some fashion... perhaps with Pfizer funding a Phase 2 or 3 using multiple and higher doses. The earlier Phase 2 trial did show efficacy at 4 weeks, but not enough to meet the endpoints. That trial was run with only a single low dose. The CEO of ATHX made some statements that indicated he thought higher and repeated doses could make a difference. The above is speculation, but if Pfizer announces that they're pursuing an additional Phase 2 or 3 using higher and repeated doses, it'll be a bullish sign... as it'll indicate they have some confidence in Multi-Stem. I could see this running back up over $2 on that news alone. jck clinicaltrials.gov/archive/NCT01240915/2014_10_29/changes |
|
|
|
Post by dayanand33 on Oct 31, 2014 17:41:50 GMT
Sell, RLC: Found some other interesting information... The UC trial has been updated (see clinicaltrials.gov link below) with new locations. The updates were made 2 days ago on 10/29. As you know, the UC trial was the one funded and run by Pfizer, and early this year they announced it did not meet the Phase 2 efficacy endpoints. That was the reason ATHX plummeted from the $4s to the low $1s. Well, these changes on clinicaltrials.gov include new sites and changes to the status of the trial from "closed" to "Active Not Recruiting". While I can't be sure, it appears that this trial is continuing on in some fashion... perhaps with Pfizer funding a Phase 2 or 3 using multiple and higher doses. The earlier Phase 2 trial did show efficacy at 4 weeks, but not enough to meet the endpoints. That trial was run with only a single low dose. The CEO of ATHX made some statements that indicated he thought higher and repeated doses could make a difference. The above is speculation, but if Pfizer announces that they're pursuing an additional Phase 2 or 3 using higher and repeated doses, it'll be a bullish sign... as it'll indicate they have some confidence in Multi-Stem. I could see this running back up over $2 on that news alone. jck clinicaltrials.gov/archive/NCT01240915/2014_10_29/changesO Boy! you are comments are moving the market! |
|
|
|
Post by selluwud on Oct 31, 2014 17:45:52 GMT
Sell, RLC: Found some other interesting information... The UC trial has been updated (see clinicaltrials.gov link below) with new locations. The updates were made 2 days ago on 10/29. As you know, the UC trial was the one funded and run by Pfizer, and early this year they announced it did not meet the Phase 2 efficacy endpoints. That was the reason ATHX plummeted from the $4s to the low $1s. Well, these changes on clinicaltrials.gov include new sites and changes to the status of the trial from "closed" to "Active Not Recruiting". While I can't be sure, it appears that this trial is continuing on in some fashion... perhaps with Pfizer funding a Phase 2 or 3 using multiple and higher doses. The earlier Phase 2 trial did show efficacy at 4 weeks, but not enough to meet the endpoints. That trial was run with only a single low dose. The CEO of ATHX made some statements that indicated he thought higher and repeated doses could make a difference. The above is speculation, but if Pfizer announces that they're pursuing an additional Phase 2 or 3 using higher and repeated doses, it'll be a bullish sign... as it'll indicate they have some confidence in Multi-Stem. I could see this running back up over $2 on that news alone. jck clinicaltrials.gov/archive/NCT01240915/2014_10_29/changesO Boy! you are comments are moving the market! By all means, keep commenting, keep commenting. I like green. |
|
|
|
Post by jckrdu on Oct 31, 2014 18:05:39 GMT
Nah... it ain't me, but thanks for those thoughts.  Lots of news pending... those 2 clinicaltrial.gov updates for UC and AMI over the past week have renewed interest here. Stroke enrollment completing (PR any day IMO) should help stabilize the pps and enable the next leg higher. |
|
|
|
Post by hophead on Nov 1, 2014 0:45:44 GMT
Thanks for the tip a few weeks ago on this one jim. Up pretty nice about 30% so far.
|
|
|
|
Post by RLC on Nov 1, 2014 1:10:08 GMT
Sell, RLC: Found some other interesting information... The UC trial has been updated (see clinicaltrials.gov link below) with new locations. The updates were made 2 days ago on 10/29. As you know, the UC trial was the one funded and run by Pfizer, and early this year they announced it did not meet the Phase 2 efficacy endpoints. That was the reason ATHX plummeted from the $4s to the low $1s. Well, these changes on clinicaltrials.gov include new sites and changes to the status of the trial from "closed" to "Active Not Recruiting". While I can't be sure, it appears that this trial is continuing on in some fashion... perhaps with Pfizer funding a Phase 2 or 3 using multiple and higher doses. The earlier Phase 2 trial did show efficacy at 4 weeks, but not enough to meet the endpoints. That trial was run with only a single low dose. The CEO of ATHX made some statements that indicated he thought higher and repeated doses could make a difference. The above is speculation, but if Pfizer announces that they're pursuing an additional Phase 2 or 3 using higher and repeated doses, it'll be a bullish sign... as it'll indicate they have some confidence in Multi-Stem. I could see this running back up over $2 on that news alone. jck clinicaltrials.gov/archive/NCT01240915/2014_10_29/changesThanks for the updates on this one Jim. I added a small position a few days ago at $1.38 and will likely add another chunk next week depending on the PPS action. I agree that this seems like a great play for the next 3-6 months. |
|
|
|
Post by selluwud on Nov 1, 2014 12:31:11 GMT
This is my largest equity holding at the moment. Since I can't keep my eye on it 24/7 I will put some type trailing stop in place to protect my profits. This should move up until profit taking before data reveal.
|
|
|
|
Post by jckrdu on Nov 1, 2014 14:05:01 GMT
Sell, RLC: Found some other interesting information... The UC trial has been updated (see clinicaltrials.gov link below) with new locations. The updates were made 2 days ago on 10/29. As you know, the UC trial was the one funded and run by Pfizer, and early this year they announced it did not meet the Phase 2 efficacy endpoints. That was the reason ATHX plummeted from the $4s to the low $1s. Well, these changes on clinicaltrials.gov include new sites and changes to the status of the trial from "closed" to "Active Not Recruiting". While I can't be sure, it appears that this trial is continuing on in some fashion... perhaps with Pfizer funding a Phase 2 or 3 using multiple and higher doses. The earlier Phase 2 trial did show efficacy at 4 weeks, but not enough to meet the endpoints. That trial was run with only a single low dose. The CEO of ATHX made some statements that indicated he thought higher and repeated doses could make a difference. The above is speculation, but if Pfizer announces that they're pursuing an additional Phase 2 or 3 using higher and repeated doses, it'll be a bullish sign... as it'll indicate they have some confidence in Multi-Stem. I could see this running back up over $2 on that news alone. jck clinicaltrials.gov/archive/NCT01240915/2014_10_29/changesGood to see you guys catching the move up off the lows. I was watching this stock all summer looking for the right time to move back in, so I'm very happy to get in when I did. I'm not sure how fast it'll move up to the $1.80 - $2.00 range, but I do think we'll get there over the next 90 days. Really depends on what type of news they announce, hopefully starting next week 11/3. Next earnings conference call is the following Monday, 11/10... I'm expecting some type of news before that call. On the UC trial per my post above, the below link may be better to look at, as I reset the filters at the top so the location changes appear. Using the below link, if you scroll down you can see the locations where the status was changed from "Terminated" to "Active Not Recruiting". Also, the very first entry was an "addition" via the green legend at the bottom of the page; they added an EU clinicl trial identifier which is 2010-022766-27. Hard not to conclude that the completed Phase 2 UC trial is moving forward in some new fashion. We'll see. ATHX is an interesting company, as they have a very cautious/stealth/measured way of releasing news. If folks don't listen to their presenattions, a lot of the recent developments go unnoticed. I kind of like that approach, because if you do a little digging you can put new developments together before they're officially disclosed to the market. clinicaltrials.gov/archive/NCT01240915/2014_10_29/changes |
|
|
|
Post by jckrdu on Nov 3, 2014 15:45:00 GMT
Sell, RLC: Found some other interesting information... The UC trial has been updated (see clinicaltrials.gov link below) with new locations. The updates were made 2 days ago on 10/29. As you know, the UC trial was the one funded and run by Pfizer, and early this year they announced it did not meet the Phase 2 efficacy endpoints. That was the reason ATHX plummeted from the $4s to the low $1s. Well, these changes on clinicaltrials.gov include new sites and changes to the status of the trial from "closed" to "Active Not Recruiting". While I can't be sure, it appears that this trial is continuing on in some fashion... perhaps with Pfizer funding a Phase 2 or 3 using multiple and higher doses. The earlier Phase 2 trial did show efficacy at 4 weeks, but not enough to meet the endpoints. That trial was run with only a single low dose. The CEO of ATHX made some statements that indicated he thought higher and repeated doses could make a difference. The above is speculation, but if Pfizer announces that they're pursuing an additional Phase 2 or 3 using higher and repeated doses, it'll be a bullish sign... as it'll indicate they have some confidence in Multi-Stem. I could see this running back up over $2 on that news alone. jck clinicaltrials.gov/archive/NCT01240915/2014_10_29/changesGood to see you guys catching the move up off the lows. I was watching this stock all summer looking for the right time to move back in, so I'm very happy to get in when I did. I'm not sure how fast it'll move up to the $1.80 - $2.00 range, but I do think we'll get there over the next 90 days. Really depends on what type of news they announce, hopefully starting next week 11/3. Next earnings conference call is the following Monday, 11/10... I'm expecting some type of news before that call. On the UC trial per my post above, the below link may be better to look at, as I reset the filters at the top so the location changes appear. Using the below link, if you scroll down you can see the locations where the status was changed from "Terminated" to "Active Not Recruiting". Also, the very first entry was an "addition" via the green legend at the bottom of the page; they added an EU clinicl trial identifier which is 2010-022766-27. Hard not to conclude that the completed Phase 2 UC trial is moving forward in some new fashion. We'll see. ATHX is an interesting company, as they have a very cautious/stealth/measured way of releasing news. If folks don't listen to their presenattions, a lot of the recent developments go unnoticed. I kind of like that approach, because if you do a little digging you can put new developments together before they're officially disclosed to the market. clinicaltrials.gov/archive/NCT01240915/2014_10_29/changesNice follow-thru with higher than normal volume so far this morning. Also good to see the support at $1.50 hold - so far - as I was half expecting a little pullback/consolidation today. Perhaps with the conference call only 4 trading days away and many news items pending, investors are still in accumulation mode. |
|
|
|
Post by jckrdu on Nov 3, 2014 17:35:39 GMT
PPS starting to move higher on volume... good to see the follow-thru on both volume and pps today.
Fwiw... I'm not planning on taking any off the table until I see the $1.80s, as that'll be an approximate 50% return on my position in the $1.20s. I'm also going to wait until we get news, because if we get news that Pfizer is moving forward on a revised Phase 2 or 3 for UC, my intitial sell point is going to be much higher... probably somewhere in the low $2s as I think we'll move back over $2 on any significant UC news alone. Stroke results run-up would be additive from there, IMO. Glta.
Should be hearing something soon.
|
|
|
|
Post by selluwud on Nov 3, 2014 17:56:59 GMT
PPS starting to move higher on volume... good to see the follow-thru on both volume and pps today. Fwiw... I'm not planning on taking any off the table until I see the $1.80s, as that'll be an approximate 50% return on my position in the $1.20s. I'm also going to wait until we get news, because if we get news that Pfizer is moving forward on a revised Phase 2 or 3 for UC, my intitial sell point is going to be much higher... probably somewhere in the low $2s as I think we'll move back over $2 on any significant UC news alone. Stroke results run-up would be additive from there, IMO. Glta. Should be hearing something soon. Who can argue with 50%............Look forward to it. I'll need right at 2 to make 50%, but I'm expecting to see more. |
|
|
|
Post by jckrdu on Nov 3, 2014 18:06:30 GMT
PPS starting to move higher on volume... good to see the follow-thru on both volume and pps today. Fwiw... I'm not planning on taking any off the table until I see the $1.80s, as that'll be an approximate 50% return on my position in the $1.20s. I'm also going to wait until we get news, because if we get news that Pfizer is moving forward on a revised Phase 2 or 3 for UC, my intitial sell point is going to be much higher... probably somewhere in the low $2s as I think we'll move back over $2 on any significant UC news alone. Stroke results run-up would be additive from there, IMO. Glta. Should be hearing something soon. Who can argue with 50%............Look forward to it. I'll need right at 2 to make 50%, but I'm expecting to see more. Agree. You've been following this one just like me.... we know that ATHX was trading at these levels ($1.60s) just a few months ago. It just sold down on low volume in the absence of news over the last 2 months. I'm seeing $1.60ish as the base. News should take us higher from here. |
|
|
|
Post by hophead on Nov 4, 2014 16:59:13 GMT
Thanks for the updates guys. Really liking this stock right now. I will also probably wait until the next PR to contemplate taking profits.
|
|
|
|
Post by RLC on Nov 4, 2014 18:00:55 GMT
Thanks for the updates guys. Really liking this stock right now. I will also probably wait until the next PR to contemplate taking profits. Hah... I too am really liking this stock right now. I guess it's easy to like a stock giving you continual green days. I'm really eager to see some of the upcoming catalysts unfold and how the stock will react. Am very thankful to Jck for the heads up on this one... It's helping to heal my ACTC pain a little quicker! |
|
|
|
Post by hophead on Nov 4, 2014 18:03:53 GMT
For sure RLC. If this hits $2.50 I will forget all about the A TACO nightmare.
|
|
|
|
Post by JHam on Nov 4, 2014 19:04:42 GMT
Good like guys, I am pulling for you with this one. I am spread too thin at the moment otherwise I would consider taking a stab at this one.
hop,
Yeah, the fact of the matter is, there are several biotechs that are much more appealing at this point than ACT in my opinion. Good luck with ATHX. There has been some nice movement the past 2 days.
|
|
|
|
Post by selluwud on Nov 4, 2014 19:29:04 GMT
Today makes the third day in row (so far) that ATHX has been making notable gains. Will it retrace and then restart without any visible news to drive it higher? All bets are off with any good news.
|
|
Lots of news pending... those 2 clinicaltrial.gov updates for UC and AMI over the past week have renewed interest here. Stroke enrollment completing (PR any day IMO) should help stabilize the pps and enable the next leg higher. 
